- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04982042
Post COVID-19 Pulmonary Rehabilitation Program (COVID19REHAB)
Outpatient and Home Pulmonary Rehabilitation Program for Post COVID-19 Patients
Coronavirus-2019 disease (COVID-19) is a highly infectious respiratory disease that causes respiratory, physical and psychological dysfunction in patients.
With the increased understanding of the severity of COVID-19 and clinical evidence in accordance with the opinions of first-line clinical experts involved in the treatment of this epidemic, the investigators believe that the participation of patients with sequelae of COVID-19 in a Pulmonary Rehabilitation Program would be of utmost importance.
According to recent scientific recommendations for patients with sequelae of COVID-19, respiratory rehabilitation would alleviate symptoms of dyspnea, anxiety and depression and, eventually, improve physical functions and quality of life.
Therefore, it is essential to anticipate early rehabilitation after the acute phase of ARDS, in order to limit the severity of the effects of the ICU and promote rapid functional recovery. Physiotherapy will play a role in providing exercise, mobilization and rehabilitation interventions for survivors of critical illnesses associated with COVID-19, in order to enable a functional social return.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The investigatores propose a clinical, prospective and consecutive study composed of participants with pulmonary sequelae of COVID-19 and pulmonary diseases such as COPD, Asthma, Bronchitis, Emphysema, Bronchiectasis and pulmonary fibrosis. Initially, all patients will undergo a physical assessment, pulmonary function tests and nutritional assessment, in addition to applying the modified dyspnea scale of the MMRC (Modified Medical Research Council) and the 6-minute walk test (6MWT), according to the standards recommended by the American Thoracic Society (ATS).
The proposed Outpatient and Home Pulmonary Rehabilitation Program is based on the Guidelines recommended by the Brazilian Society of Pulmonology (SBPT) and by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), with a minimum duration of 12 weeks, frequency of 3 weekly sessions, accompanied by health professionals in this field.
Patients who seek care at municipal and state health services in the city of Anápolis, (Goiás) will be recruited. Patients with clinically stabilized COVID - 19 sequelae will be considered eligible, and who agree to participate in the study, signing the Informed Consent .
The outpatient PRP consisted of a combination of aerobic and strengthening exercises, lasting 12 weeks, frequency 3 times a week. Each session will consist of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Luis LV Oliveira, PhD
- Telefonnummer: 0055 62 999052309
- E-post: oliveira.lvf@gmail.com
Studer Kontakt Backup
- Navn: Luis VF Oliveira, PhD
- Telefonnummer: 0055 62 999052309
- E-post: luis.oliveira@unievangelica.edu.br
Studiesteder
-
-
GO
-
Anápolis, GO, Brasil, 75083-515
- Rekruttering
- Centro Universitário de Anápolis - UniEVANGÉLICA
-
Ta kontakt med:
- Luis VF Oliveira, PhD
- Telefonnummer: 6717 +55 62 33106600
- E-post: oliveira.lvf@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with a diagnosis of pulmonary sequelae post COVID-19
- Patients clinically stabilized
- Who agreed to participate in the clinical study, signing the informed consent form, will be considered eligible.
Exclusion Criteria:
- Hospitalized patients
- Patients who present clinical instability
- Patients who do not commit to adhering to the Pulmonary Rehabilitation Program
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Post COVID-19 Outpatient Pulmonary Rehabilitation Program
The outpatient Pulmonary Rehabilitation Program will be carried out at the Pulmonary Rehabilitation Laboratory, consisting of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning.
Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises.
The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
|
The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning.
Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises.
The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
|
|
Aktiv komparator: Post COVID-19 Home Pulmonary Rehabilitation Program
The Home Pulmonary Rehabilitation Program will be carried out at the patients' homes, consisting of the same combination of aerobic and strengthening exercises, lasting 12 weeks, 3 times a week, always in the morning.
Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises.
The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
Patients will be monitored weekly via whatsapp.
|
The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning.
Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises.
The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Functional status after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on levels of functional status assessed with the Medical Research Council (MRC) Scale in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Exercise capacity after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on exercise capacity assessed with the six minutes Walk Test ( 6MWT) in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Forced Vital Capacity after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on the forced vital capacity (FVC) measured by spirometry in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Forced Expiratory Volume in first second after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on the forced expiratory volume in first second (FEV1) measured by spirometry in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Inspiratory muscle strength after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on the inspiratory muscles strength measured by vacuometry in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Peripheral muscle strength after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on the peripheral muscle strength measured by Hand Grip Dynamometer in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Levels of anxiety and depression after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on the Anxiety and depression levels measured by the Hospital Anxiety and Depression scale in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Quality of Life after Pulmonary Rehabilitation Program (COVID-19REHAB)
Tidsramme: 12 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on the Quality of Life levels measured by Medical Outcomes Study/SF-36 Questionnaire in patients with pulmonary sequelae resulting from COVID-19.
|
12 weeks
|
|
Health costs after COVID - 19.
Tidsramme: 36 weeks
|
Effects of an Ambulatory and Home Pulmonary Rehabilitation Program on healthcare costs verified through the financial expenses of patients with pulmonary sequelae resulting from COVID-19.
|
36 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Luis VF OLiveira, PhD, Evangelical University of Goiás - UNIEVANGELICA
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske prosesser
- Sykdommer i nervesystemet
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Sykdommer i luftveiene
- Respirasjonsforstyrrelser
- Lungebetennelse, viral
- Lungebetennelse
- Nevrologiske manifestasjoner
- Muskel- og skjelettsykdommer
- Muskelsykdommer
- Nevromuskulære manifestasjoner
- Covid-19
- Lungesykdommer
- Muskel svakhet
- Respiratorisk insuffisiens
- Angstlidelser
- Luftveisinfeksjoner
Andre studie-ID-numre
- COVID-19 PULMONARY REHAB
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .